



Figure S7: TLR9 agonist CpG enhanced anti-tumor effects and antigen presentation of recombinant lipopeptide. (a) BMDCs or pDCs were pulsed with rIipo-OVA(100 nM) in the presence or absence of CpG (100 nM) for 18 hr. Purity > 90%. The CD8⁺ cells isolated from OT-1 mice (purity > 90 %) were cultured with protein-pulsed DCs in the ratio 5:1 for 72 hr. T cell proliferation was determined by [³H]-thymidine incorporation. (b) C57BL/6 mice (*n*=6 per group) were inoculated with 2 × 10⁴ of EG7 cells in a total volume 200 μl subcutaneously. After 3 days, 10 μg of rOVA, rIipo-OVA, rIipo-OVA/CpG or PBS was injected s.c. Tumor growth was observed three times per week. The tumor volume was shown as length × width × width/2 (mm³). Data are expressed as mean ± SEM.